{"brief_title": "Pediatric Epilepsy Study in Subjects 1-24 Months", "brief_summary": "This study will evaluate the long-term safety of LAMICTAL(lamotrigine)in subjects with partial seizures previously enrolled in protocol LAM20006 and in subjects 1-24 months of age who have never received LAMICTAL(LAMICTAL-naive). For LAMICTAL-naive subjects, LAMICTAL will be added to the subject's current epilepsy medications.", "condition": "Epilepsy", "intervention_type": "Drug", "intervention_name": "lamotrigine", "criteria": "Inclusion criteria: - Must have completed the Open-Label Phase of protocol LAM20006 or meet criteria for LAMICTAL naive subjects as follows: - A confident diagnosis of epilepsy. - 4 or more partial seizures per month. - current treatment with 1 or 2 anti-epileptic drugs. Exclusion criteria: - Has seizures not related to epilepsy. - Has a surgically implanted and functioning vagal nerve stimulator. - Has previously been treated with lamotrigine. - Is currently taking felbamate, ACTH (adrenocorticotrophic hormone) or is on the ketogenic diet. - Use of experimental medication within 30 days of enrollment.", "gender": "All", "minimum_age": "1 Month", "maximum_age": "24 Months", "healthy_volunteers": "No", "id": "NCT00044278.xml"}